Wockhardt kickstarts Global Phase 3 Clinical Study of its novel antibiotic WCK 5222

16 Aug 2022 , 09:16 AM

Wockhardt Limited announced the completion of the first site initiation visit for the pivotal Phase 3 global Clinical Study of its novel antibiotic WCK 5222.

WCK 5222 is a super-drug, an entirely new class of antibiotic known as ‘β-lactam ENHANCER’.

This is a multi-center, double-blind, efficacy, safety, and tolerability study of hospitalized adults with Complicated Urinary Tract Infections, including Acute Pyelonephritis.

This study will have 70 centres in 11 countries, including the United States, Europe, India, China, and Latin America. This global study is expected to take 18 months to complete.

When approved, Wockhardt will be the first Indian company to develop a new drug that is approved and available in countries such as the United States, Europe, India, China, and many others.

At around 9.19 AM, Wockhardt was trading at Rs230.05 down by Rs6.7 or 2.83% from its previous closing of Rs236.75 on the BSE. The scrip opened at Rs230.55.